Symbols / SLS Stock $4.46 -3.88% SELLAS Life Sciences Group, Inc.
SLS (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Ratings
Current target
$4.46
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-12 | main | Maxim Group | Buy → Buy | $10 |
| 2025-07-16 | main | Maxim Group | Buy → Buy | $7 |
| 2023-11-22 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2023-09-07 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2022-11-15 | main | Alliance Global Partners | — → Buy | $8 |
| 2022-06-28 | main | Cantor Fitzgerald | — → Overweight | $6 |
| 2021-07-21 | init | Cantor Fitzgerald | — → Overweight | $18 |
| 2019-11-15 | up | Maxim Group | Hold → Buy | $12 |
| 2019-04-08 | init | Alliance Global Partners | — → Buy | $5 |
| 2018-11-01 | init | Oppenheimer | — → Outperform | $13 |
| 2018-07-20 | main | Maxim Group | Buy → Buy | $5 |
| 2018-04-02 | init | HC Wainwright & Co. | — → Buy | $11 |
| 2018-03-19 | up | Maxim Group | Hold → Buy | — |
News
RSS: Latest SLS news- SLS stock sparks retail buzz ahead of AACR presentation on experimental cancer therapy - MSN Sun, 26 Apr 2026 01
- SLS Stock Jumps Premarket: US Investor Dagco Boosts Stake By 78% Ahead Of Fresh Cancer Drug Data Reveal - Stocktwits Fri, 24 Apr 2026 22
- BlackRock (SLS) discloses 12.14M shares, 6.8% ownership (Schedule 13G/A) - Stock Titan Fri, 24 Apr 2026 20
- Sellas Life Sciences: Behind The Big Surge (NASDAQ:SLS) - Seeking Alpha Wed, 22 Apr 2026 11
- Sellas Life Sciences draws significant retail buzz as traders eye REGAL phase 3 catalyst – SLS stock soars 15% - MSN Sun, 26 Apr 2026 09
- SELLAS Life Sciences "Hold" As Phase 3 AML Study Progresses To Key Event (NASDAQ:SLS) - Seeking Alpha hu, 23 Apr 2026 19
- SLS Stock Slips After-Hours As Cancer Pipeline Silence Frustrates Retail — China Licensing Fight Now In Spotlight - Stocktwits hu, 23 Apr 2026 18
- SLS stock slips after-hours as cancer pipeline silence frustrates retail — China licensing fight now in spotlight - MSN Sun, 26 Apr 2026 12
- SLS stock jumps premarket: US investor Dagco boosts stake by 78% ahead of fresh cancer drug data reveal - MSN Sun, 26 Apr 2026 10
- SLS vs ATNM: Which cancer stock has bigger upside ahead of fresh data reveal? - MSN Sun, 26 Apr 2026 08
- SLS stock breaches $5 level after over 3 years: Retail now eyes buyout for as much as $25B - MSN Sun, 26 Apr 2026 01
- SLS stock rallies ahead of AML trial readout — 'Pharma Bro' Martin Shkreli says he's still 'very bearish,' predicts drug will fail - MSN Sun, 26 Apr 2026 05
- SLS stock jumps after Merck's Tern deal sparks buyout buzz in blood-cancer space: Retail bets on this big pharma suitor - MSN Sat, 25 Apr 2026 19
- SELLAS Life Sciences falls for fourth straight session — what’s driving the sell-off? - MSN Sat, 25 Apr 2026 19
- SLS stock in spotlight: First AML patient enrolled in phase 2 leukemia trial - MSN Fri, 24 Apr 2026 13
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
1.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
-100.00%
|
1.00
|
| Cost Of Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Reconciled Cost Of Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Gross Profit |
|
—
|
—
|
0.00
-100.00%
|
0.90
|
| Operating Expense |
|
28.27
-10.28%
|
31.51
-16.78%
|
37.87
+15.28%
|
32.85
|
| Research And Development |
|
16.02
-16.10%
|
19.10
-20.46%
|
24.01
+18.45%
|
20.27
|
| Selling General And Administration |
|
12.25
-1.33%
|
12.42
-10.42%
|
13.86
+10.17%
|
12.58
|
| General And Administrative Expense |
|
12.25
-1.33%
|
12.42
-10.42%
|
13.86
+10.17%
|
12.58
|
| Other Gand A |
|
12.25
-1.33%
|
12.42
-10.42%
|
13.86
+10.17%
|
12.58
|
| Total Expenses |
|
28.27
-10.28%
|
31.51
-16.78%
|
37.87
+14.93%
|
32.95
|
| Operating Income |
|
-28.27
+10.28%
|
-31.51
+16.78%
|
-37.87
-18.53%
|
-31.95
|
| Total Operating Income As Reported |
|
-28.27
+10.28%
|
-31.51
+16.78%
|
-37.87
+9.73%
|
-41.95
|
| EBITDA |
|
-28.27
+10.28%
|
-31.51
+16.78%
|
-37.87
-18.53%
|
-31.95
|
| Normalized EBITDA |
|
-28.27
+10.28%
|
-31.51
+16.79%
|
-37.87
-69.97%
|
-22.28
|
| EBIT |
|
-28.27
+10.28%
|
-31.51
+16.78%
|
-37.87
-18.53%
|
-31.95
|
| Total Unusual Items |
|
—
|
—
|
0.00
+100.04%
|
-9.67
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
0.00
+100.04%
|
-9.67
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-9.70
|
| Other Special Charges |
|
—
|
—
|
—
|
10.00
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
0.00
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
0.00
+100.00%
|
-0.30
|
| Net Income |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Pretax Income |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Net Non Operating Interest Income Expense |
|
1.41
+123.26%
|
0.63
+20.38%
|
0.53
+65.62%
|
0.32
|
| Net Interest Income |
|
1.41
+123.26%
|
0.63
+20.38%
|
0.53
+65.62%
|
0.32
|
| Interest Income Non Operating |
|
1.41
+123.26%
|
0.63
+20.38%
|
0.53
+65.62%
|
0.32
|
| Interest Income |
|
1.41
+123.26%
|
0.63
+20.38%
|
0.53
+65.62%
|
0.32
|
| Other Income Expense |
|
—
|
—
|
0.00
+100.04%
|
-9.67
|
| Gain On Sale Of Security |
|
—
|
—
|
0.00
-88.89%
|
0.04
|
| Tax Provision |
|
—
|
—
|
—
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Net Income From Continuing And Discontinued Operation |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Net Income Continuous Operations |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Normalized Income |
|
-26.86
+13.01%
|
-30.88
+17.31%
|
-37.34
-18.05%
|
-31.63
|
| Net Income Common Stockholders |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Otherunder Preferred Stock Dividend |
|
—
|
—
|
—
|
—
|
| Diluted EPS |
|
-0.25
+50.00%
|
-0.50
+62.69%
|
-1.34
+37.09%
|
-2.13
|
| Basic EPS |
|
-0.25
+50.00%
|
-0.50
+62.69%
|
-1.34
+37.09%
|
-2.13
|
| Basic Average Shares |
|
109.05
+78.18%
|
61.20
+120.33%
|
27.78
+43.21%
|
19.40
|
| Diluted Average Shares |
|
109.05
+78.18%
|
61.20
+120.33%
|
27.78
+43.21%
|
19.40
|
| Diluted NI Availto Com Stockholders |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
78.34
+303.18%
|
19.43
+212.46%
|
6.22
-70.31%
|
20.94
|
| Current Assets |
|
75.21
+360.65%
|
16.33
+414.72%
|
3.17
-82.14%
|
17.76
|
| Cash Cash Equivalents And Short Term Investments |
|
71.79
+417.02%
|
13.89
+448.85%
|
2.53
-85.23%
|
17.12
|
| Cash And Cash Equivalents |
|
71.79
+417.02%
|
13.89
+448.85%
|
2.53
-85.23%
|
17.12
|
| Receivables |
|
—
|
—
|
—
|
—
|
| Prepaid Assets |
|
3.10
+32.21%
|
2.34
+331.92%
|
0.54
+11.75%
|
0.48
|
| Restricted Cash |
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
+0.00%
|
0.10
|
| Other Current Assets |
|
0.22
|
—
|
—
|
0.05
|
| Total Non Current Assets |
|
3.13
+0.93%
|
3.10
+1.90%
|
3.05
-4.39%
|
3.19
|
| Net PPE |
|
0.96
+4.11%
|
0.93
+7.81%
|
0.86
-1.83%
|
0.87
|
| Gross PPE |
|
0.96
+4.11%
|
0.93
+7.81%
|
0.86
-1.83%
|
0.87
|
| Other Properties |
|
0.96
+4.11%
|
0.93
+7.81%
|
0.86
-1.83%
|
0.87
|
| Goodwill And Other Intangible Assets |
|
1.91
+0.00%
|
1.91
+0.00%
|
1.91
+0.00%
|
1.91
|
| Goodwill |
|
1.91
+0.00%
|
1.91
+0.00%
|
1.91
+0.00%
|
1.91
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
0.40
|
| Other Non Current Assets |
|
0.26
-3.38%
|
0.27
-3.27%
|
0.28
-31.08%
|
0.40
|
| Total Liabilities Net Minority Interest |
|
7.47
-25.01%
|
9.97
-29.79%
|
14.20
-11.79%
|
16.09
|
| Current Liabilities |
|
7.02
-26.21%
|
9.51
-30.76%
|
13.73
-11.47%
|
15.52
|
| Payables And Accrued Expenses |
|
4.68
-34.55%
|
7.15
-39.20%
|
11.75
-14.23%
|
13.70
|
| Payables |
|
2.95
-15.77%
|
3.50
-37.93%
|
5.64
-36.33%
|
8.86
|
| Accounts Payable |
|
2.95
-15.77%
|
3.50
-37.93%
|
5.64
+67.98%
|
3.36
|
| Other Payable |
|
—
|
—
|
—
|
5.50
|
| Current Accrued Expenses |
|
1.73
-52.56%
|
3.65
-40.36%
|
6.12
+26.16%
|
4.85
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.75
-1.35%
|
1.78
+19.02%
|
1.49
+3.75%
|
1.44
|
| Current Debt And Capital Lease Obligation |
|
0.54
+0.00%
|
0.54
+21.97%
|
0.45
+19.89%
|
0.37
|
| Current Capital Lease Obligation |
|
0.54
+0.00%
|
0.54
+21.97%
|
0.45
+19.89%
|
0.37
|
| Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Current Deferred Revenue |
|
—
|
—
|
—
|
—
|
| Other Current Liabilities |
|
0.04
+0.00%
|
0.04
+0.00%
|
0.04
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.46
+0.00%
|
0.46
-0.65%
|
0.46
-20.28%
|
0.58
|
| Long Term Debt And Capital Lease Obligation |
|
0.46
+0.00%
|
0.46
-0.65%
|
0.46
-19.72%
|
0.57
|
| Long Term Capital Lease Obligation |
|
0.46
+0.00%
|
0.46
-0.65%
|
0.46
-19.72%
|
0.57
|
| Non Current Deferred Liabilities |
|
—
|
—
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
—
|
—
|
—
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
70.87
+648.77%
|
9.46
+218.67%
|
-7.98
-264.42%
|
4.85
|
| Common Stock Equity |
|
70.87
+648.77%
|
9.46
+218.67%
|
-7.98
-264.42%
|
4.85
|
| Capital Stock |
|
0.01
+114.29%
|
0.01
+133.33%
|
0.00
+50.00%
|
0.00
|
| Common Stock |
|
0.01
+114.29%
|
0.01
+133.33%
|
0.00
+50.00%
|
0.00
|
| Preferred Stock |
|
—
|
—
|
0.00
|
0.00
|
| Share Issued |
|
153.10
+106.96%
|
73.98
+130.22%
|
32.13
+52.97%
|
21.01
|
| Ordinary Shares Number |
|
153.10
+106.96%
|
73.98
+130.22%
|
32.13
+52.97%
|
21.01
|
| Additional Paid In Capital |
|
345.84
+34.27%
|
257.58
+23.09%
|
209.26
+13.27%
|
184.75
|
| Retained Earnings |
|
-274.99
-10.83%
|
-248.12
-14.21%
|
-217.24
-20.76%
|
-179.90
|
| Total Equity Gross Minority Interest |
|
70.87
+648.77%
|
9.46
+218.67%
|
-7.98
-264.42%
|
4.85
|
| Total Capitalization |
|
70.87
+648.77%
|
9.46
+218.67%
|
-7.98
-264.42%
|
4.85
|
| Working Capital |
|
68.19
+900.35%
|
6.82
+164.54%
|
-10.56
-571.35%
|
2.24
|
| Invested Capital |
|
70.87
+648.77%
|
9.46
+218.67%
|
-7.98
-264.42%
|
4.85
|
| Total Debt |
|
1.00
+0.00%
|
1.00
+10.49%
|
0.91
-4.13%
|
0.94
|
| Capital Lease Obligations |
|
1.00
+0.00%
|
1.00
+10.49%
|
0.91
-4.13%
|
0.94
|
| Net Tangible Assets |
|
68.96
+813.22%
|
7.55
+176.35%
|
-9.89
-436.74%
|
2.94
|
| Tangible Book Value |
|
68.96
+813.22%
|
7.55
+176.35%
|
-9.89
-436.74%
|
2.94
|
| Derivative Product Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-28.39
+19.81%
|
-35.40
-12.71%
|
-31.41
-31.92%
|
-23.81
|
| Cash Flow From Continuing Operating Activities |
|
-28.39
+19.81%
|
-35.40
-12.71%
|
-31.41
-31.92%
|
-23.81
|
| Net Income From Continuing Operations |
|
-26.86
+13.01%
|
-30.88
+17.30%
|
-37.34
+9.59%
|
-41.30
|
| Other Non Cash Items |
|
0.60
+6.42%
|
0.56
+13.33%
|
0.49
-95.13%
|
10.16
|
| Stock Based Compensation |
|
1.96
+25.06%
|
1.56
-25.31%
|
2.09
+21.32%
|
1.73
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
0.00
|
| Deferred Tax |
|
—
|
—
|
—
|
0.00
|
| Deferred Income Tax |
|
—
|
—
|
—
|
0.00
|
| Operating Gains Losses |
|
—
|
—
|
-0.00
+88.89%
|
-0.04
|
| Gain Loss On Investment Securities |
|
—
|
—
|
-0.00
+88.89%
|
-0.04
|
| Change In Working Capital |
|
-4.08
+38.62%
|
-6.65
-298.68%
|
3.35
-40.70%
|
5.64
|
| Change In Receivables |
|
—
|
—
|
—
|
0.00
|
| Change In Prepaid Assets |
|
-0.97
+45.92%
|
-1.79
-1684.07%
|
0.11
-90.98%
|
1.25
|
| Change In Payables And Accrued Expense |
|
-2.48
+42.72%
|
-4.32
-215.28%
|
3.75
-22.82%
|
4.86
|
| Change In Accrued Expense |
|
-1.94
+11.13%
|
-2.18
-250.72%
|
1.45
-60.26%
|
3.65
|
| Change In Payable |
|
-0.54
+74.99%
|
-2.14
-192.96%
|
2.30
+89.69%
|
1.21
|
| Change In Account Payable |
|
-0.54
+74.99%
|
-2.14
-192.96%
|
2.30
+89.69%
|
1.21
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Liabilities |
|
-0.64
-19.14%
|
-0.53
-2.90%
|
-0.52
-9.98%
|
-0.47
|
| Investing Cash Flow |
|
—
|
0.00
+100.00%
|
-5.50
-22.22%
|
-4.50
|
| Cash Flow From Continuing Investing Activities |
|
—
|
0.00
+100.00%
|
-5.50
-22.22%
|
-4.50
|
| Capital Expenditure |
|
—
|
—
|
-5.50
-22.22%
|
-4.50
|
| Net Intangibles Purchase And Sale |
|
—
|
0.00
+100.00%
|
-5.50
-22.22%
|
-4.50
|
| Purchase Of Intangibles |
|
—
|
0.00
+100.00%
|
-5.50
-22.22%
|
-4.50
|
| Financing Cash Flow |
|
86.30
+84.56%
|
46.76
+109.54%
|
22.32
-7.33%
|
24.08
|
| Cash Flow From Continuing Financing Activities |
|
86.30
+84.56%
|
46.76
+109.54%
|
22.32
-7.33%
|
24.08
|
| Net Common Stock Issuance |
|
23.05
-50.07%
|
46.16
+107.71%
|
22.23
-7.37%
|
23.99
|
| Proceeds From Stock Option Exercised |
|
63.77
+9591.79%
|
0.66
+443.80%
|
0.12
+42.35%
|
0.09
|
| Net Other Financing Charges |
|
-0.53
-723.44%
|
-0.06
-106.45%
|
-0.03
|
—
|
| Changes In Cash |
|
57.91
+409.92%
|
11.36
+177.81%
|
-14.60
-245.04%
|
-4.23
|
| Beginning Cash Position |
|
13.99
+431.79%
|
2.63
-84.73%
|
17.23
-19.72%
|
21.45
|
| End Cash Position |
|
71.89
+414.04%
|
13.99
+431.79%
|
2.63
-84.73%
|
17.23
|
| Free Cash Flow |
|
-28.39
+19.81%
|
-35.40
+4.09%
|
-36.91
-30.38%
|
-28.31
|
| Common Stock Issuance |
|
23.05
-50.07%
|
46.16
+107.71%
|
22.23
-7.37%
|
23.99
|
| Issuance Of Capital Stock |
|
23.05
-50.07%
|
46.16
+107.71%
|
22.23
-7.37%
|
23.99
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-19 View
- 10-K2026-03-19 View
- 8-K2026-03-11 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 42026-01-09 View
- 8-K2026-01-08 View
- 42025-12-05 View
- 42025-12-05 View
- 42025-12-05 View
- 42025-11-21 View
- 8-K2025-11-12 View
- 10-Q2025-11-12 View
- 8-K2025-10-27 View
- 8-K2025-10-03 View
- 8-K2025-09-11 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|